Benitec Biopharma (BNTC) Gains from Investment Securities (2019 - 2025)

Benitec Biopharma's (BNTC) quarterly Gains from Investment Securities came in at $2.0 million in Q4 2025, down 60.1% quarter-over-quarter from $4.9 million in Q2 2025.

Benitec Biopharma (BNTC) Gains from Investment Securities (2019 - 2025) Analysis & Trends

Benitec Biopharma has disclosed Gains from Investment Securities across 4 years of filings, most recently posting $2.0 million for Q4 2025.

  • Gains from Investment Securities for Q4 2025 came in at $2.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $2.0 million (changed N/A YoY), and the FY2025 annual result was $4.9 million, changed N/A from the prior year.
  • Gains from Investment Securities came in at $2.0 million for Q4 2025 at Benitec Biopharma, down from $4.9 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $4.9 million in Q2 2025 to a low of $794000.0 in Q3 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 788,338.31 Bn 788,338.28 Bn -
2 Belite Bio 56,560.00 Bn 56,560.00 Bn -
3 Quantum Biopharma 17,329.30 Bn 17,329.30 Bn -
4 Legend Biotech 3,341.00 Bn 3,340.71 Bn 242.10 Mn
5 Akari Therapeutics 1,727.91 Bn 1,727.91 Bn -
6 Evaxion A 1,536.68 Bn 1,536.67 Bn -
7 Psyence Biomedical 238.34 Bn 238.33 Bn -
8 Vertex Pharmaceuticals 113.42 Bn 106.17 Bn 2.59 Bn
9 Abivax 95.45 Bn 95.45 Bn -
10 Benitec Biopharma 488.21 Mn 488.21 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 1.96 Mn
Dec 31, 2025 1.96 Mn
Jun 30, 2025 4.90 Mn
Jun 30, 2025 4.90 Mn
Sep 30, 2021 794,000.00
Sep 30, 2021 794,000.00
Mar 31, 2020 -580,000.00
Mar 31, 2020 -580,000.00
Dec 31, 2019 580,000.00
Dec 31, 2019 580,000.00
Sep 30, 2019 -1,000.00
Sep 30, 2019 -1,000.00